Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Altimmune, Inc. Common Stock

ALT

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Last trade $1.56
Day change -$0.005 (-0.32%)
Day range $1.50 – $1.60
Volume 2,569,790
Market cap $304M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$303.56M
Price / earnings
—
Price / book
0.68×
Price / sales
11,675.37×
EV / sales
11,910.02×
EV / EBITDA
-2.69×

Profitability

Earnings per share
-$0.54
Return on assets
-21.11%
Return on equity
-23.59%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.08×
Current ratio
23.93×
Quick ratio
23.93×
Cash ratio
2.51×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$102.47M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ALT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$26K$5K$5K$5K$5K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$26K$5K$5K$5K$5K
Selling, general and administrative$8.69M$7.57M$8.05M$10.51M$5.9M$5.69M$5.99M$5.09M
Research and development$27.02M$18.66M$16.19M$18.41M$14.96M$17.24M$15.83M$19.78M
Total operating expenses$35.71M$26.23M$24.24M$28.92M$20.86M$22.93M$21.82M$24.87M
Operating income-$35.71M-$26.23M-$24.24M-$28.89M-$20.86M-$22.92M-$21.82M-$24.87M
Interest expense-$1.12M-$1.1M-$1.07M-$876K-$495K-$264K-$1K-$1K
Income before taxes-$31.61M-$22.83M-$22.56M-$27.36M-$19.01M-$22.15M-$20.26M-$23.18M
Income taxes$0$0$0$0$0$0-$681K$0
Net income-$31.61M-$22.83M-$22.56M-$27.36M-$19.01M-$22.15M-$19.58M-$23.18M
Net income attributable to common shareholders-$31.61M-$22.83M-$22.86M-$27.36M-$19.01M-$22.15M-$19.61M-$23.18M
EBITDA-$35.69M-$26.21M-$24.22M-$28.87M-$20.83M-$22.89M-$21.79M-$24.83M
Basic earnings per share-$0.15-$0.12-$0.18-$0.26-$0.21-$0.27-$0.26-$0.33
Diluted earnings per share-$0.15-$0.12-$0.18-$0.26-$0.21-$0.27-$0.26-$0.33

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns

Altimmune reported a Q3 2026 loss of 15 cents per share, missing consensus estimates by one cent. R&D expenses surged 80.6% to $27 million due to ongoing pemvidutide clinical studies. The company has $480 million in cash expected to fund operations into 2029. Stock declined 17% following the announcement due to concerns over rising development costs and funding uncertainty for the planned phase III AUD program.

GlobeNewswire Inc.

Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026

Altimmune announced that its RECLAIM Phase 2 trial data for pemvidutide, a dual glucagon/GLP-1 receptor agonist, in treating alcohol use disorder (AUD) has been accepted as a late-breaking oral presentation at AASLD The Liver Meeting 2026. The trial met its primary endpoint of reducing heavy drinking days and key secondary endpoints. The company is scheduled to meet with the FDA in December for an End-of-Phase 2 meeting to discuss Phase 3 registrational plans.

GlobeNewswire Inc.

Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight

The MASH (Metabolic Dysfunction-Associated Steatohepatitis) market is rapidly expanding with over 180 companies developing 200+ pipeline therapies. Two drugs have been approved: REZDIFFRA (resmetirom) by Madrigal Pharmaceuticals and LIPAGLYN/BILYPSA (saroglitazar magnesium) by Zydus Lifesciences. The competitive landscape is intensifying with emerging mechanisms of action including FGF21 replacements, GLP-1 receptor agonists, and dual glucagon/GLP-1 agonists, with approximately 5+ drugs in late-stage development and 100+ in mid and early stages.

Zacks Investment Research

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?

Novo Nordisk is expanding semaglutide into new indications like MASH and obesity-related conditions to diversify revenue beyond its core GLP-1 franchise. However, the company faces significant competitive pressure from Eli Lilly's broad incretin portfolio expansion and other competitors in the MASH market. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation with a Hold rating.

Zacks Investment Research

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune reported a Q2 2026 loss of 12 cents per share, beating the consensus estimate of 15 cents, with no revenues as the company lacks marketed drugs. R&D expenses rose 8.2% to $18.7 million, primarily due to ongoing MASH clinical studies. The company's cash position strengthened to $519 million, supporting operations into 2029. Shares have gained 14.2% over the past month, outperforming the S&P 500, though the stock carries a Zacks Rank #3 (Hold) rating with an overall VGM Score of F.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 14, 20181-for-30reverse split
May 4, 20171-for-10reverse split
Jul 25, 20071-for-50reverse split